Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

Literature DB >> 26521258

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

David Ternant¹, Gilles Paintaud², Howard Trachtman³, Debbie S Gipson⁴, Melanie S Joy⁵.

Abstract

Entities: Chemical Gene

Mesh：

Substances：
Adalimumab

Year: 2015 PMID： 26521258 DOI： 10.1007/s00228-015-1973-1

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

× No keyword cloud information.

8 in total

1. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Authors: Gabriel J Robbie; Liang Zhao; John Mondick; Genevieve Losonsky; Lorin K Roskos
Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191

2. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Authors: Adedigbo A Fasanmade; Omoniyi J Adedokun; Marion Blank; Honghui Zhou; Hugh M Davis
Journal: Clin Ther Date: 2011-07-07 Impact factor: 3.393

3. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

Authors: Konstantinos Karmiris; Gilles Paintaud; Maja Noman; Charlotte Magdelaine-Beuzelin; Marc Ferrante; Danielle Degenne; Karolien Claes; Tamara Coopman; Nele Van Schuerbeek; Gert Van Assche; Severine Vermeire; Paul Rutgeerts
Journal: Gastroenterology Date: 2009-08-05 Impact factor: 22.682

4. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Authors: Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink
Journal: Ann Rheum Dis Date: 2007-02-14 Impact factor: 19.103

5. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Authors: Melanie S Joy; Debbie S Gipson; Mary Dike; Leslie Powell; Amber Thompson; Suzanne Vento; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal: Clin J Am Soc Nephrol Date: 2008-12-10 Impact factor: 8.237

6. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors: Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal: Am J Kidney Dis Date: 2009-11-22 Impact factor: 8.860

7. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Authors: David Ternant; Emilie Ducourau; Piéra Fuzibet; Céline Vignault; Hervé Watier; Thierry Lequerré; Xavier Le Loët; Olivier Vittecoq; Philippe Goupille; Denis Mulleman; Gilles Paintaud
Journal: Br J Clin Pharmacol Date: 2015-02 Impact factor: 4.335

Review 8. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Authors: Helena Edlund; Johanna Melin; Zinnia P Parra-Guillen; Charlotte Kloft
Journal: Clin Pharmacokinet Date: 2015-01 Impact factor: 5.577

8 in total

4 in total

A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).

1. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

2. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

3. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

4. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

5. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

6. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

7. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Review 8. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

1. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.

Review 2. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Review 3. Interventions for focal segmental glomerulosclerosis in adults.

Review 4. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.